A 24 year old woman with myasthenia gravis suffered an antepartum exacerbation which failed to respond to increasing dosages of pyridostigmine. Thymectomy performed in the second trimester was followed by clinical improvement and fuli term vaginal delivery with no puerperal deterioration.
Introduction
The course of myasthenia gravis in pregnancy is unpredictable (Giwa-Osagie et al., 1981) . Complete remission, clinical improvement, acute exacerbations or no change in myasthenic symptoms have been reported. Anticholinesterase drugs and steroid treatment are the mainstays of medical therapy during pregnancy (Plauche, 1979) . Thymectomy in the management of a pregnant myasthenic patient is rarely indicated and has not been documented previously.
Case report
A 24 year old Chinese primigravid woman first presented with ptosis and weakness of the lower limbs 2 years earlier. Myasthenia gravis was diagnosed by the edrophonium test in which 10 mg of edrophonium intravenously produced marked improvement of ptosis and muscle power while normal saline produced no response. Electromyography showed decremental response in muscle action potential on repetitive supramaximal stimulation ofthe ulnar nerve. Pyridostigmine (Mestinon) 120 mg five times a day was administered with good control of her myasthenic symptoms until she was 8 weeks pregnant.
She then developed dysphagia and dysarthria, progressive proximal muscle weakness and mild respiratory muscle involvement. The dose of pyridostigmine was adjusted by repeated edrophonium test to 180 mg five times a day but the patient remained weak. Transsternal thymectomy was performed at the 17th gestational week. Histological examination revealed thymic hyperplasia. Postoperatively, she required mechanical ventilation for 8 days. Pyridostigmine was re-introduced on the second postoperative day and the dosage was adjusted by repeated edrophonium tests. The postoperative course was complicated by collapse of the left lung on the fifth day because the endotracheal tube had entered the right bronchus. Bronchial lavage was done with re-expansion of the left lung in one day. She was weaned off the respirator on the seventh postoperative day with the endotracheal tube retained for 2 more days for aspiration of copious bronchial secretion. She was discharged home on the 17th postoperative day, maintained on pyridostigmine 180mg six times a day.
She went into spontaneous labour at the 39th gestational week, delivering a male infant of 3,169 g by vacuum extraction for slight meconium-stained liquor. Mild neonatal myasthenia was detected, which responded well to pyridostigmine treatment. No postpartum deterioration of her myasthenia was observed and within 4 weeks ofdelivery, her condition stabilized while she returned to pre-pregnancy dosage of pyridostigmine of 120mg five times a day.
Discussion
Thymectomy has become established in the treatment of myasthenia gravis since it leads to significant clinical improvement, lower anticholinesterase requirement and complete remission in a proportion of cases (Buckingham et al., 1976) . The risk of thymectomy has lessened with experience in the surgical techniques and facilities for intensive care. Study of the use of thymectomy in young, non-pregnant female myasthenic patients has demonstrated increased incidence of remission and decreased incidence of exacerbation during pregnancy in the thymectomy group (Eden & Gall, 1983) . However, there is no documented report of thymectomy during pregnancy for the control of myasthenic crisis. Our patient, who received pyridostigmine alone without steroid treatment, illustrates the beneficial outcome following midtrimester thymectomy. Thymectomy should be considered in the management of deteriorating myasthenia gravis during pregnancy as an alternative to steroid therapy or plasmapheresis.
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